Tetracosanol

Tetracosanol (1-Tetracosanol / Lignoceryl Alcohol)

1. Identity and Chemical Characterization

Names, Classification, and Physical Properties

1-Tetracosanol, also known as lignoceryl alcohol, tetracosan-1-ol, lignocerol, tetracosyl alcohol, and n-tetracosanol, is a long-chain primary saturated fatty alcohol. 1-Tetracosanol (lignoceryl alcohol) is a fatty alcohol containing 24 carbon atoms, usually derived from the fatty acid lignoceric acid. Its linear molecular formula is CH₃(CH₂)₂₃OH, it carries CAS Registry Number 506-51-4, a molecular weight of 354.65 g/mol, and EC Number 208-043-9. Its molecular formula is C₂₄H₅₀O, molecular weight 354.66, melting point 74–77 °C, and it appears as a white to light yellow powder or crystal.

ChEBI describes tetracosanol as a long-chain primary fatty alcohol that is tetracosane in which a hydrogen attached to one of the terminal carbons is replaced by a hydroxy group. By systematic IUPAC nomenclature it is tetracosan-1-ol. The NIST WebBook lists it under the synonyms lignoceric alcohol, lignoceryl alcohol, 1-tetracosanol, tetracosan-1-ol, tetracosyl alcohol, lignocerol, and tetracosanol.

Position Within the Policosanol Family

Tetracosanol is the shortest-chain member of the nutritionally relevant policosanol group. Policosanols are long-chain fatty alcohols ranging from 24 to 34 carbons in length. Pure policosanol exists as a white powder or scaly crystal and is a mixture of molecules with carbon chains ranging in length from 24 to 34 carbons, known as tetratriacontanol (C-34), dotriacontanol (C-32), triacontanol (C-30), nonacosanol (C-29), octacosanol (C-28), heptacosanol (C-27), hexacosanol (C-26), and tetracosanol (C-24).

Within commercial policosanol preparations, tetracosanol is present at a minority fraction. In one characterized policosanol preparation, alcohol content yielded 66% octacosanol (C28), 17% triacontanol (C30), 6% hexacosanol (C26), 5% dotriacontanol (C32), and 2% tetracosanol (C24). Cuban sugarcane-derived policosanol formulations contain 1-tetracosanol (C24H₄₉OH; molecular weight 354.7) at ≤2%, while 1-octacosanol constitutes ≤60–70% of the mixture.

However, the relative abundance of tetracosanol varies considerably depending on the botanical source. In rice bran oil in particular, tetracosanol is notably more prominent. In rice bran oil (RBO), the most abundant policosanol is tetracosanol (C-24; 60.50 mg/100 g), followed by hexacosanol (C-26; 54.61 mg/100 g), octacosanol (C-28; 48.32 mg/100 g), triacontanol (45.10 mg/100 g), and dotriacontanol (45.81 mg/100 g).

2. Natural Sources

Tetracosanol is distributed widely in the plant and insect kingdoms, occurring most commonly in the surface waxes and cuticle layers of plants. Policosanol, of which tetracosanol is a constituent, is extracted from sugarcane (Saccharum officinarum L.) wax, wheat germ, beeswax, and rice. It is a regular monohydric primary alcohol which can be extracted from rice bran, sugar cane, germ, maize, beeswax, apples, grapes, etc.

It has been isolated from a variety of plants, including grape seeds, evening primrose (Oenothera biennis), pitaya fruits (Hylocereus polyrhizus and Hylocereus undatus), and the flowers of Arabian jasmine (Jasminum sambac). Among the policosanols isolated from tomato seed oil are tetracosanol, hexacosanol, and octacosanol. 1-Tetracosanol has also been isolated from roots and pomace olive oil.

In olive oil by-products it occurs as part of the non-glyceride fraction. Long-chain fatty alcohols were isolated from the non-glyceride fraction of pomace olive oil, and the major components of these long-chain fatty alcohols were tetracosanol, hexacosanol, and octacosanol.

Natural policosanol in plants is present in an esterified form, but the extraction method releases a fatty acid and a free fatty alcohol. In processed supplements and standardized extracts, the material is typically obtained by alkaline saponification (hydrolysis) of wax esters, liberating the free fatty alcohols including tetracosanol.

3. Common Forms and Preparations

Tetracosanol is rarely supplied as a standalone supplement. It is encountered commercially almost exclusively as a minor constituent of policosanol preparations, which are standardized mixtures of long-chain fatty alcohols. Policosanol is a mixture of long-chain aliphatic alcohols (24–34 carbons), including tetracosanol, hexacosanol, heptacosanol, octacosanol, nonacosanol, triacontanol, dotriacontanol, and tetratriacontanol; it was originally isolated from purified sugarcane wax, but similar alcohols are also found in rice bran and beeswax.

Pharmaceutical policosanol compositions typically contain 70%–95% of C24–C36 alkanols, comprising 75%–90% (w/w) of 1-octacosanol and 5%–15% (w/w) of a mixture of 1-tetracosanol, 1-hexacosanol, 1-heptacosanol, 1-triacontanol, and 1-tetratriacontanol. Commercial preparations are available as oral tablets (commonly 5 mg and 10 mg dosage units), with extraction methods including supercritical carbon dioxide processes. A commercially viable process for producing higher fatty alcohols (C24–C36) uses a novel technique of supercritical carbon dioxide extraction that incorporates an immobilized hydrolyzing enzyme.

For research purposes, high-purity (≥97–99%) isolated 1-tetracosanol is available as a white to light yellow crystalline solid from chemical suppliers such as Sigma-Aldrich and TCI, used in in vitro and preclinical pharmacological studies. In two studies on 5–10 mg capsules of policosanol, the product was found stable for up to 9 months under ambient storage conditions, with some degradation noted into fatty acid esters from the alcohol form.

4. Traditional and Historical Use

Tetracosanol as an isolated compound has no independently documented history of traditional use; its ethnobotanical footprint derives from its presence in plant materials used in traditional medicine systems. The policosanol-rich waxes and oils containing tetracosanol appear in the traditional use histories of their source plants rather than as a deliberately isolated chemical entity.

Sugarcane (Saccharum officinarum), the most commercially significant source of policosanol wax, has documented use across South Asian and Caribbean traditional medicine, where sugarcane preparations have been used for digestive complaints, wound healing, and as tonics. Wheat germ oil, another source, has been used as a traditional food supplement and general tonic in the 20th century, particularly for athletic preparation, though these uses are ascribed primarily to vitamin E and octacosanol content rather than to tetracosanol specifically.

In traditional Chinese medicine, the insect wax produced by Ericerus pela (Chinese white wax scale insect), which contains policosanols including tetracosanol, has historically been used as a topical preparation. Policosanol is a mixture of long-chain fatty alcohols exhibiting multiple biological activities such as reducing blood lipid and cholesterol levels, lowering blood pressure, and extenuating liver inflammation; policosanol was prepared from Ericerus pela wax using a reduction method.

The scientific study of policosanol as a supplement began in earnest in Cuba during the late 1980s and early 1990s, when researchers at the National Center for Scientific Research in Havana isolated and characterized the fatty alcohol mixture from sugarcane wax and commenced systematic clinical investigation. The anticholesterolaemic activity and some desirable pleiotropic effects (decreased platelet aggregation, LDL oxidation, thromboxane production, and foam-cell production) of the original policosanol have been confirmed by more than 50 clinical studies. These studies used sugarcane-derived preparations in which tetracosanol was present at ≤2%.

5. Key Constituents and Established Mechanisms of Action

Chemical Context: Tetracosanol Within the Policosanol Mixture

When studying mechanisms of action, it is important to recognize that most mechanistic research has been conducted on the whole policosanol mixture or on its dominant constituent octacosanol, with tetracosanol implicated either as a co-active component or studied in targeted experiments. Octacosanol is seen as the primary bioactive fatty alcohol whereas triacontanol is seen as a significant source of bioactivity as well; the others should be noted as their bioactivity may be relevant.

AMP-Activated Protein Kinase (AMPK) Pathway and Cholesterol Regulation

The best-characterized mechanism associated with long-chain fatty alcohols is activation of AMP-activated protein kinase (AMPK), a central regulator of cellular energy metabolism. Policosanols have demonstrated inhibitory action on HMG-CoA reductase and on bile acid absorption, in addition to an activating effect on AMPK (increase of fatty acid β-oxidation). Policosanol binds to the β-subunit of AMP-activated protein kinase (AMPK) and activates the AMPK pathway, which inhibits the activity of HMG-CoA reductase, leading to increased receptor-mediated uptake of LDL in the liver by increasing the number of hepatic LDL receptors.

Policosanol promotes bile acid production and lipolysis via inhibiting the expression of farnesoid X receptor–small heterodimer partner and activating the Takeda G-coupled protein receptor 5–AMPK signaling pathway, which inhibits HMG-CoA reductase activity. Including 0.5% policosanol in the diet activates AMPK and AMPK-related gene expression, leading to decreased fatty acid synthesis and inflammation while promoting lipolysis and thermogenesis in adipose tissue.

The requirement for peroxisomal metabolism in AMPK activation by policosanols has been specifically investigated. These alcohols were anticipated to decrease cholesterol synthesis through the activation of AMP-kinase and subsequent inactivation of HMG-CoA reductase. The exact mechanism underlying AMPK activation by tetracosanol specifically has not been fully elucidated and remains an area of ongoing investigation.

Anti-Inflammatory Mechanisms

Tetracosanol has been specifically studied for anti-inflammatory activity. In the landmark Fernández-Arche et al. (2009) study, long-chain fatty alcohols were isolated from the non-glyceride fraction of pomace olive oil, with the major components being tetracosanol, hexacosanol, and octacosanol. The study investigated these compounds' ability to inhibit the release of different proinflammatory mediators in vitro; the long-chain fatty alcohols significantly and dose-dependently decreased nitric oxide production by RAW 264.7 murine macrophages stimulated with lipopolysaccharide, with Western blot analysis showing that nitric oxide reduction was a consequence of the inhibition of inducible nitric oxide synthase expression. These long-chain fatty alcohols also reduced tumor necrosis factor-α and prostaglandin E2 production.

The proposed molecular mechanism involves inactivation of the nuclear transcription factor NF-κB. Long-chain fatty alcohols might modulate nitric oxide release by acting on inducible NOS transcription, probably by inactivating the nuclear transcription factor NF-κB, just as statins do.

Glucose Metabolism and Insulin Signaling

Preclinical data specifically for tetracosanol indicate activity in insulin signaling pathways. Tetracosanol can improve glycaemic control via insulin receptor kinase activity and leads to enhancement of glucose transporter translocation to improve glucose uptake; insulin plus tetracosanol restored the ability of glucose transporter translocation and glucose uptake in differentiated myotubes with S961-induced insulin resistance in vitro. The modification of carbon chain lengths and the hydroxyl group of tetracosanol showed it served as a critical chemical structure for the glucostasis effect in vivo; tetracosanol can improve glycaemic control via insulin receptor kinase activity-induced enhancement of glucose transporter translocation; the hydroxyl group of tetracosanol plays a critical role for insulin receptor kinase activity.

Lipid Peroxidation and Antioxidant Activity

AMPK activation inhibits cholesteryl ester transfer protein (CETP), and policosanol's actions on HDL-C and LDL-C binding increase LDL-C catabolism while lowering triglyceride metabolism. Policosanol also has anti-platelet effects as well as the ability to prevent lipoprotein peroxidation. These broader antioxidant-related effects have been attributed to the policosanol mixture as a whole.

6. Scientific Evidence by Area of Use

6.1 Lipid Metabolism and Cardiovascular Risk

The most extensively studied application of policosanol — the natural vehicle for tetracosanol — is the modulation of blood lipid profiles. Research conducted by small research groups, many located in Cuba, has shown reductions of total cholesterol (17% to 21%), LDL-C (21% to 29%), and TG (12% to 15%), and increases in HDL-C (8% to 15%). However, a controlled study conducted in Germany found less than a 10% reduction in LDL-C from policosanol doses of 10, 20, 40, and 80 mg/day.

A 2023 meta-analysis provided more nuanced findings. In a meta-analysis of 22 randomized controlled trials with 1,886 participants with dyslipidemia, policosanol supplementation was associated with a decrease in total cholesterol (−0.58 mmol/L; 95% CI, −0.87 to −0.30) and LDL-C (−0.71 mmol/L; 95% CI, −1.02 to −0.40) and an increase in HDL-C (0.13 mmol/L; 95% CI, 0.09 to 0.16).

The geographic and source-dependent controversy is well documented. Policosanol is a mixture of oils from Cuban cane sugar, touted as a cholesterol-lowering agent and showing potency at this claim in several studies released from Cuba; other studies undermine the quality of these, however, and the matter remains controversial. In recent years several clinical studies have suggested a reducing action of this nutraceutical on lipid profile, but results are often non-significant; the Berthold et al. study showed that administration of policosanols in hypercholesterolemic patients does not statistically improve the levels of TC, TG, HDL-C, or LDL-C in a trial including 143 subjects divided into five groups treated with 10, 20, 40, or 80 mg of policosanols or placebo.

An important confound is source heterogeneity: different policosanol preparations have very different constituent alcohol profiles, meaning that tetracosanol's proportion in any studied mixture varies. Based on all these data, policosanol should not be recommended in clinical practice until new well-designed studies are performed that definitively clarify its lipid-lowering potential effect.

A human clinical study specifically investigating sugar cane policosanol for HDL function reported: the study was designed to investigate the physiological effects of policosanol consumption for 8 weeks on the quality of lipoproteins in young and middle-aged subjects, comparing the functionality of lipoproteins and expression levels of apolipoproteins as well as changes in body fat, blood pressure, and serum lipid profiles. These data make agreement that policosanol can enhance HDL functionality via AMPK activation and CETP inhibition.

Evidence strength: Evidence is mixed. Cuban-derived clinical data are positive but methodologically questioned. Independent multi-centre and European trials have failed to replicate the magnitude of effect. Tetracosanol's individual contribution to these lipid outcomes cannot be isolated from the mixture data.

6.2 Anti-Inflammatory Activity

The primary evidence for anti-inflammatory activity attributable specifically to tetracosanol comes from in vitro (cell-based) studies. Fernández-Arche et al. (2009) demonstrated the anti-inflammatory potential of tetracosanol, hexacosanol, and octacosanol isolated from pomace olive oil to reduce the release of different inflammatory mediators — tumor necrosis factor-α, prostaglandin E2, and nitric oxide — in lipopolysaccharide-stimulated RAW 264.7 murine macrophages.

Long-chain fatty alcohols reduced TNF production by LPS-stimulated RAW 264.7 macrophages, but only at the highest concentration tested (100 μg/mL). The authors hypothesized a mechanism involving NF-κB inhibition. This effect would also be mediated by NF-κB activation, a transcription factor also involved in COX-2 transcription, the enzyme responsible for the synthesis of PGE2.

Evidence strength: Preliminary. Evidence is entirely in vitro (cell culture) and animal-based. No human clinical trials have assessed tetracosanol specifically for inflammatory outcomes. Extrapolation to human inflammatory disease is not currently supported.

6.3 Glycemic Control and Insulin Resistance

Tetracosanol has been specifically investigated as a potential anti-diabetic agent in preclinical models. The role of tetracosanol as an anti-diabetic agent from a natural compound has not yet been widely reported. Preclinical experiments used an insulin receptor antagonist (S961) to induce hyperglycemia in mouse models.

In 8-week-old male C57BL/6 mice fasted for 12 hours, oral administration of tetracosanol (dissolved in PEG and EtOH, 25 mg/kg body weight) or metformin (100 mg/kg body weight) was compared over 3 hours. In the hyperglycemic mice model, the glycemic control effect of tetracosanol was confirmed by oral glucose tolerance test (OGTT), comparing groups treated with metformin as a positive control, tetracosanol, or neither, all administered D-glucose (2 g/kg body weight). It was suggested that tetracosanol serves as a potential agent for glycemic control via enhancement of glucose transporter 4 (GLUT4) translocation that improves glucose uptake.

Evidence strength: Early-stage preclinical only. All evidence is in animal models and in vitro cell lines. No human clinical data exist evaluating tetracosanol specifically for glycemic control. The finding regarding GLUT4 translocation is mechanistically interesting but requires clinical translation.

6.4 Platelet Aggregation and Antithrombotic Effects

Antiplatelet activity is one of the best-supported biological effects attributed to the policosanol class. Policosanol is a cholesterol-lowering drug with hypocholesterolemic effects demonstrated in experimental models, healthy volunteers, and type II hypercholesterolemic patients; in addition, antiplatelet effects of policosanol have been shown in experimental models and healthy volunteers.

A rat study specifically examined the interaction between policosanol and warfarin: the study investigated the effects of the concomitant administration of policosanol and warfarin on bleeding time and experimentally induced venous thrombosis in rats; policosanol did not change the bleeding time, whereas warfarin alone and the combination policosanol + warfarin induced a moderate but significant prolongation of bleeding time; the addition of policosanol to warfarin therapy did not enhance the prolongation of bleeding time induced by warfarin alone; a significant reduction of thrombus weight was observed after policosanol or warfarin monotherapies.

Tetracosanol's specific contribution to antiplatelet activity within the policosanol mixture has not been isolated in dedicated human clinical studies. The antiplatelet data pertain to the mixture as a whole.

Evidence strength: Moderate for the mixture. The antiplatelet effect of policosanol is supported by multiple studies, but attribution to tetracosanol specifically is not established.

6.5 Cognitive Function

Animal model research has examined policosanol from Ericerus pela wax — containing tetracosanol as a constituent — for effects on learning and memory. Policosanol is a mixture of long-chain fatty alcohols that exhibits multiple biological activities, such as reducing blood lipid and cholesterol levels, lowering blood pressure, and extenuating liver inflammation. Policosanol was prepared from Ericerus pela wax and assessed in 60 mice randomly divided into six groups of 10 animals each, administered daily for 28 consecutive days, with parameters including escape latency, crossings of platform, swimming distance, and time spent in the target quadrant in the Morris Water Maze to evaluate cognitive performance.

Evidence strength: Preclinical only. No human clinical evidence exists evaluating tetracosanol or policosanol mixtures specifically for cognitive outcomes. The animal data are suggestive but preliminary.

6.6 Liver Enzyme Effects

Significant reductions in liver enzymes have been observed in some studies. However, the impact of policosanol on liver enzymes remained controversial. A meta-analysis aimed to evaluate the effect of policosanol supplementation on the levels of alanine transaminase (ALT) and aspartate transaminase (AST) with literature systematically searched through PubMed/Medline, Google Scholar, EMBASE, and Scopus; only randomized controlled trial studies comparing policosanol to placebo were included.

Evidence strength: Insufficient and mixed. The available evidence on hepatic enzyme effects of policosanol mixtures (which include tetracosanol) is inconclusive, and tetracosanol alone has not been studied for these outcomes in humans.

7. Body Systems and Health Areas

• Cardiovascular system: Investigated as part of policosanol for cholesterol lowering (total cholesterol, LDL-C reduction; HDL-C elevation), blood pressure modulation, inhibition of platelet aggregation, and reduction of thrombus formation.
• Immune / inflammatory system: In vitro evidence for suppression of pro-inflammatory mediators (TNF-α, PGE2, NO) via iNOS inhibition and putative NF-κB pathway modulation.
• Endocrine / metabolic system: Preclinical evidence for enhancement of insulin receptor kinase activity, GLUT4 translocation, and improved glycemic control in insulin-resistant animal models.
• Hepatic system: Presence within rice bran oil and sugarcane wax mixtures that have been studied for effects on liver enzymes and fatty liver; evidence is indirect and mixed.
• Central nervous system: Animal model evidence for cognitive benefit within policosanol mixtures; no human data for tetracosanol specifically.
• Adipose / energy metabolism: Via AMPK pathway, policosanol constituents (including tetracosanol) are associated with promotion of fatty acid β-oxidation, lipolysis, and thermogenesis in animal models.

8. Dosage Forms and Reported Dosages

Because tetracosanol has been studied almost exclusively as a constituent of policosanol mixtures, dosage data pertain to those mixtures. The following are doses reported in sources:

• The typical dose of policosanol ranges from 5 to 20 mg.
• The suggested starting dose for policosanol is 10 mg daily, taken in the evening.
• The maximum benefit appears to be obtained with 20 mg/day.
• Policosanol is typically initiated at 5 mg/day and titrated up to 20 mg/day for hypercholesterolemia; adjunctive use of 40 mg/day for 30 days has been used with antiplatelet regimens after percutaneous stent implantation.
• Clinical studies have most commonly used 5 to 20 mg of policosanol per day, with 10 mg being the standard dose in the majority of trials.
• In preclinical animal studies for glycemic control: tetracosanol was administered orally at 25 mg/kg body weight in mice.
• In an animal study on cognitive function: policosanol doses tested were 2 g/kg (low), 4 g/kg (medium), and 6 g/kg (high) by intragastric gavage in mice.
• In a human study, commercially available policosanol tablets of 10 mg each were used.

At the ≤2% content of tetracosanol in typical Cuban sugarcane-derived policosanol, a 10 mg dose of policosanol would deliver approximately ≤0.2 mg of tetracosanol. In rice bran oil sources, the proportion is higher.

9. Safety Considerations and Drug Interactions

General Tolerability

Animal and human studies have demonstrated few adverse reactions from policosanol; limited animal and human studies have found policosanol to be safe. The tolerability of policosanols is usually very good. Advantages of policosanol are its good tolerability and extremely low incidence of adverse events (side effects), which does not require frequent laboratory tests.

Animal toxicity data for octacosanol (the dominant related compound) are broadly reassuring: as early as 1994, toxicity studies reported that the oral LD50 of octacosanol in rats was as high as 18 g/kg, indicating its safety and supporting its use as a functional component. Studies in rats and mice demonstrated no adverse effects on fertility, reproduction, teratogenesis, or development at doses equivalent to 1,500 times the normal human dose of 20 mg/day.

Antiplatelet / Anticoagulant Interactions

The most clinically significant interaction concern for policosanol involves its antiplatelet activity. Taking policosanol along with medications that also slow clotting might increase the chances of bruising and bleeding; relevant medications include aspirin, clopidogrel (Plavix), diclofenac, ibuprofen, naproxen, dalteparin, enoxaparin, heparin, and warfarin (Coumadin).

However, a specific clinical pharmacokinetic study provides nuance: a study in 11 healthy men receiving warfarin 25 mg before and after treatment with policosanol 10 mg twice daily for 2 weeks found no effect of policosanol on the pharmacokinetics of (S)- or (R)-warfarin; policosanol also did not alter the response to warfarin on platelet aggregation.

Data suggest that adverse events due to drug-to-drug interactions with policosanol are not relevant; experimental data indicate that potential drug-to-drug interactions between policosanol and drugs metabolized through the cytochrome P450 hepatic system are not expected, but pharmacodynamic interactions cannot be excluded.

Antihypertensive Drug Interactions

Policosanol might decrease blood pressure in some people; taking policosanol along with medications used for lowering high blood pressure might cause blood pressure to go too low. Several clinical studies have shown that policosanol decreased arterial pressure compared with placebo, and a pharmacological interaction with beta-blockers was experimentally proven.

Blood Sugar Interactions

Policosanol might lower blood sugar; taking it with other supplements with similar effects might lower blood sugar too much; examples of supplements with this effect include aloe, bitter melon, cassia cinnamon, chromium, and prickly pear cactus.

Levodopa Interaction

There is a reported interaction with levodopa, a Parkinson's disease medication; at least one non-Cuban study suggested policosanol could amplify levodopa's effects and side effects, particularly involuntary movements.

Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.

Source and Compositional Variability: A Critical Safety and Efficacy Caveat

A fundamental challenge in evaluating the safety and efficacy of tetracosanol and policosanol mixtures is the significant variability in alcohol composition across different source plants and preparations. Outcomes from clinical studies on botanical-derived natural product efficacy for health maintenance and disease risk reduction often yield mixed results, driven in part by the varying composition of the experimental interventions investigated. This variability means that the tetracosanol content — and thus any potential activity attributable specifically to it — differs markedly between preparations derived from sugarcane, rice bran, beeswax, or other sources.

References

• PubChem National Library of Medicine — 1-Tetracosanol (CID 10472)
• Sigma-Aldrich — Lignoceryl alcohol (1-Tetracosanol), CAS 506-51-4
• NIST WebBook — n-Tetracosanol-1 (CAS 506-51-4)
• Fernández-Arche et al. (2009). Long-chain fatty alcohols from pomace olive oil modulate the release of proinflammatory mediators. Pharmacological Research. ScienceDirect.
• Fernández-Arche et al. (2009) — ResearchGate entry: Long-chain fatty alcohols from pomace olive oil modulate the release of proinflammatory mediators
• Fernández-Arche et al. — Long-chain fatty alcohols from pomace olive oil (CSIC preprint/repository PDF)
• PMC — Fatty Acid Esterification of Octacosanol Attenuates Triglyceride and Cholesterol Synthesis in Mice (2025)
• PMC — Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects (2017)
• PMC — Consumption of Cuban Policosanol Improves Blood Pressure and Lipid Profile via Enhancement of HDL Functionality in Healthy Women: Randomized, Double-Blinded, Placebo-Controlled Study (2018)
• PMC — Activation of AMP-kinase by Policosanol Requires Peroxisomal Metabolism (2011)
• PMC — Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia (2023)
• PMC — Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel (2017)
• PMC — Improving Effect of Policosanol from Ericerus pela Wax on Learning and Memory Impairment Caused by Scopolamine in Mice (2022)
• PMC — Oleic Acid-Esterified Octacosanol as a Functional Ingredient to Counter Obesity-Associated Lipid Dysregulation through PPAR-Targeted Regulation (2025)
• ScienceDirect — Policosanol: Extraction and biological functions (2019)
• ScienceDirect Topics — Policosanol overview
• Longdom Open Access — Effects of Cuban Sugarcane-Derived Policosanol on Lipid Profiles in Healthy Individuals: Systematic Review and Meta-Analysis (2025)
• PubMed — Interaction policosanol-warfarin on bleeding time and thrombosis in rats (1998)
• PubMed — Concomitant use of policosanol and beta-blockers in older patients (2005)
• Drugs.com Natural Products Database — Policosanol: Uses, Benefits & Dosage
• Examine.com — Research Breakdown on Policosanol
• Springer — Policosanol: updating and perspectives. Mediterranean Journal of Nutrition and Metabolism (2008)
• USPTO Patent 9226950 — Method and composition for treating diabetes mellitus (tetracosanol glycemic control)
• Taylor & Francis Knowledge Centre — 1-Tetracosanol
• PMC — The Importance of Reference Materials and Method Validation for Advancing Research on Dietary Supplements (2021)